Geoffrey C. Farrell
#116,612
Most Influential Person Now
Geoffrey C. Farrell's AcademicInfluence.com Rankings
Geoffrey C. Farrellmedical Degrees
Medical
#1683
World Rank
#2049
Historical Rank
Gastroenterology
#24
World Rank
#26
Historical Rank
Geoffrey C. Farrellphilosophy Degrees
Philosophy
#5094
World Rank
#7817
Historical Rank
Logic
#2427
World Rank
#3417
Historical Rank
Download Badge
Medical Philosophy
Why Is Geoffrey C. Farrell Influential?
(Suggest an Edit or Addition)Geoffrey C. Farrell's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) (2381)
- Nonalcoholic fatty liver disease: From steatosis to cirrhosis (2006) (2379)
- Lamivudine for patients with chronic hepatitis B and advanced liver disease. (2004) (2235)
- NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome (2002) (1131)
- Beyond insulin resistance in NASH: TNF‐α or adiponectin? (2004) (762)
- CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. (2000) (711)
- Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression (2003) (664)
- Etiopathogenesis of nonalcoholic steatohepatitis. (2001) (664)
- Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis (1998) (590)
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. (2017) (587)
- Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. (2005) (542)
- A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis (2018) (481)
- Epidemiology of non-alcoholic fatty liver disease in China. (2009) (475)
- Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice (2003) (459)
- Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary (2007) (443)
- Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C (2003) (433)
- Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection (2003) (419)
- Leptin is essential for the hepatic fibrogenic response to chronic liver injury. (2002) (393)
- NAFLD in Asia—as common and important as in the West (2013) (393)
- Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. (1996) (387)
- Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response (2002) (378)
- Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? (2002) (364)
- NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications (2012) (355)
- Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice (2004) (342)
- Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. (2001) (329)
- Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment (2018) (319)
- Non‐alcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines (2007) (318)
- Independent effects of physical activity in patients with nonalcoholic fatty liver disease (2009) (315)
- Human cytochromes P450 (1999) (303)
- Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. (2003) (295)
- Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. (2011) (289)
- NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. (2005) (271)
- Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease (1995) (246)
- Hepatic Microcirculation in Fatty Liver Disease (2008) (241)
- HFE mutations, hepatic iron, and fibrosis: Ethnic‐specific association of NASH with C282Y but not with fibrotic severity (2002) (239)
- Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region? (2003) (237)
- Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. (2003) (223)
- Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis (2013) (220)
- Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. (2004) (212)
- Drugs and steatohepatitis. (2002) (205)
- Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index (2004) (200)
- Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice (2004) (199)
- Which patients with hepatitis C develop liver complications? (2000) (186)
- A fresh look at NASH pathogenesis. Part 1: The metabolic movers (2010) (179)
- Genotype‐specific mechanisms for hepatic steatosis in chronic hepatitis C infection (2002) (175)
- Fatty liver disease: NASH and related disorders (2004) (172)
- Coinfection with hepatitis B and C or B, C and δ viruses results in severe chronic liver disease and responds poorly to terferon‐a treatment (1995) (168)
- Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis (2019) (164)
- COX‐2 induction in mice with experimental nutritional steatohepatitis: Role as pro‐inflammatory mediator (2006) (162)
- Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground (2011) (157)
- Hepatic ischemic preconditioning in mice is associated with activation of NF‐κB, p38 kinase, and cell cycle entry (2002) (155)
- Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? (2006) (155)
- Non‐alcoholic steatohepatitis in the Asia–Pacific region: Future shock? (2004) (154)
- Herbal hepatotoxicity: An expanding but poorly defined problem (2000) (150)
- Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo (2006) (148)
- Hepatitis C virus in intravenous drug users (1990) (147)
- CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. (2014) (145)
- Drug-induced liver disease (2000) (142)
- Insulin resistance and liver injury in hepatitis C is not associated with virus‐specific changes in adipocytokines (2007) (141)
- Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. (2016) (138)
- Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? (2011) (135)
- Low‐dose TNF‐α protects against hepatic ischemia‐reperfusion injury in mice: Implications for preconditioning (2003) (133)
- Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. (2014) (131)
- Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. (1998) (131)
- Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. (1995) (130)
- Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression (2009) (122)
- Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. (2006) (120)
- Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. (1999) (120)
- MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. (2008) (115)
- INHIBITION OF THEOPHYLLINE METABOLISM BY INTERFERON (1987) (115)
- Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. (1995) (115)
- Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors (2009) (113)
- Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling (2018) (113)
- Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. (2013) (109)
- Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. (2018) (107)
- Hepatotoxic slimming aids and other herbal hepatotoxins (2008) (104)
- Inhibition of antipyrine metabolism by interferon. (1986) (104)
- Mechanisms and Implications of Age-Related Changes in the Liver: Nonalcoholic Fatty Liver Disease in the Elderly (2011) (101)
- Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. (1995) (101)
- Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. (2003) (101)
- Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. (2001) (100)
- The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups (2018) (99)
- Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. (1998) (95)
- Dual role of tumor necrosis factor‐α in hepatic ischemia‐reperfusion injury: Studies in tumor necrosis factor‐α gene knockout mice (2004) (94)
- Epidemiology of hepatitis C virus infection in Australia (1993) (92)
- Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection (2008) (90)
- Coffee and non‐alcoholic fatty liver disease: Brewing evidence for hepatoprotection? (2014) (88)
- Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice. (2006) (85)
- Plasma gaba, gaba‐like activity and the brain gaba‐benzodiazepine receptor complex in rats with chronic hepatic encephalopathy (1987) (84)
- Drug-induced cholestasis (2003) (81)
- Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH[S] (2017) (81)
- Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice (2009) (81)
- Drug metabolism in cirrhosis. Selective changes in cytochrome P-450 isozymes in the choline-deficient rat model. (1986) (79)
- Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. (2004) (79)
- AMPK Activation Prevents and Reverses Drug-Induced Mitochondrial and Hepatocyte Injury by Promoting Mitochondrial Fusion and Function (2016) (78)
- How should we manage patients with non‐alcoholic fatty liver disease in 2007? (2007) (76)
- Activation of peroxisome proliferator‐activated receptor α by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation (2008) (74)
- Brain γ-aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma γ-aminobutyric acid-like activity (1987) (73)
- Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. (2003) (73)
- MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. (2006) (72)
- Peroxisome proliferator‐activated receptor‐α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non‐alcoholic steatohepatitis (2012) (69)
- Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. (1990) (69)
- Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. (2008) (69)
- Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. (2007) (69)
- Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. (2006) (68)
- Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. (2009) (67)
- Postprandial hyperinsulinemia is universal in non‐diabetic patients with nonalcoholic fatty liver disease (2011) (67)
- Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. (2000) (67)
- Strain dependence of diet‐induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype (2014) (65)
- The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C (1994) (65)
- Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study (2004) (64)
- Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. (1998) (62)
- A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice (2013) (61)
- Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway (2014) (60)
- Interferon suppresses erythromycin metabolism in rats and human subjects (1993) (60)
- Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH (2015) (59)
- The effects of cell density, attachment substratum and dexamethasone on spontaneous apoptosis of rat hepatocytes in primary culture (1999) (57)
- Does steatohepatitis impair liver regeneration? A study in a dietary model of non‐alcoholic steatohepatitis in rats (1999) (56)
- Dual role of tumor necrosis factor-alpha in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-alpha gene knockout mice. (2004) (56)
- Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor alpha. (1995) (55)
- High sensitivity C‐reactive protein values do not reliably predict the severity of histological changes in NAFLD (2004) (54)
- The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice (2017) (53)
- Lymphoblastoid interferon alfa‐n1 improves the long‐term response to a 6‐month course of treatment in chronic hepatitis C compared with recombinant interferon alfa‐2b: Results of an international randomized controlled trial (1998) (53)
- Signalling links in the liver: knitting SOCS with fat and inflammation. (2005) (52)
- Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health (2007) (52)
- Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice (2015) (51)
- Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C (2005) (50)
- TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. (2017) (50)
- New hepatitis C guidelines for the Asia–Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection (2007) (49)
- Downregulation of male‐specific cytochrome P450s 2C11 and 3A2 in bile duct–ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis (1995) (49)
- Drug‐induced hepatic injury (1997) (48)
- Role of oxidative stress in hypoxia‐reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells (2000) (48)
- Prevention of hepatocellular carcinoma complicating chronic hepatitis C (2009) (47)
- Drug metabolism in extrahepatic diseases. (1987) (45)
- Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? (1991) (44)
- Release of Ca2+ from the endoplasmic reticulum is not the mechanism for bile acid-induced cholestasis and hepatotoxicity in the intact rat liver. (1990) (44)
- The central role of sinusoidal endothelial cells in hepatic hypoxia‐reoxygenation injury in the rat (1996) (44)
- Atorvastatin protects obese mice against hepatic ischemia–reperfusion injury by Toll‐like receptor‐4 suppression and endothelial nitric oxide synthase activation (2012) (43)
- Management of chronic hepatitis B virus infection: a new era of disease control (2006) (43)
- Effect of liver regeneration on hepatic cytochrome P450 isozymes and serum sex steroids in the male rat. (1989) (43)
- NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. (2007) (43)
- Incorporation of exogenous heme into hepatic cytochrome P-450 in vivo. (1979) (43)
- Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. (1998) (43)
- Insulin resistance, obesity, and liver cancer. (2014) (42)
- Liver cholesterol: is it playing possum in NASH? (2012) (41)
- Interferon γ down‐regulates cytochrome P450 3A genes in primary cultures of well‐differentiated rat hepatocytes (1996) (41)
- VAT fat is bad for the liver, SAT fat is not! (2008) (41)
- Short‐term therapy with peroxisome proliferation‐activator receptor‐α agonist Wy‐14,643 protects murine fatty liver against ischemia–reperfusion injury (2010) (40)
- Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH (2021) (40)
- Prevention of hepatocellular carcinoma in nonviral‐related liver diseases (2009) (40)
- Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes. (1997) (40)
- Microparticles Mediate Hepatic Ischemia-Reperfusion Injury and Are the Targets of Diannexin (ASP8597) (2014) (40)
- Impaired androgen 16 alpha-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats. (1987) (39)
- Hepatotoxicity from paracetamol self‐poisoning in western Sydney: a continuing challenge (1992) (38)
- Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression. (1990) (38)
- Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis. (1989) (38)
- Ethanol reduces p38 kinase activation and cyclin D1 protein expression after partial hepatectomy in rats. (2006) (38)
- Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice (2017) (38)
- Increased expression of cytochrome P450 IIIA2 in male rat liver after dietary vitamin A supplementation. (1991) (37)
- Drug-induced cholestasis. (2001) (36)
- Molecular epidemiology of hepatitis C in Australia (1998) (35)
- Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis (2019) (35)
- Human cytochrome P450 isoforms (1990) (35)
- Chronic ethanol administration to rats decreases receptor-operated mobilization of intracellular ionic calcium in cultured hepatocytes and inhibits 1,4,5-inositol trisphosphate production: relevance to impaired liver regeneration. (1996) (35)
- Structural and functional reconstitution of hepatic cytochrome P-450 in vivo. Reversal of allylisopropylacetamide-mediated destruction of the hemoprotein by exogenous heme. (1980) (34)
- Altered regulation of cytochrome P-450 enzymes in choline-deficient cirrhotic male rat liver: impaired regulation and activity of the male-specific androst-4-ene-3,17-dione 16 alpha-hydroxylase, cytochrome P-450UT-A, in hepatic cirrhosis. (1987) (33)
- Management of chronic hepatitis C virus infection: a new era of disease control (2004) (33)
- How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? (1998) (33)
- Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: Relevance to drug metabolism in experimental cholestasis (1996) (32)
- Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis. (2010) (32)
- Source of raised serum estrogens in male rats with portal bypass. (1988) (32)
- Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. (1999) (32)
- Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis (2013) (32)
- Accuracy and clinical utility of simplified tests of antipyrine metabolism. (1984) (31)
- Effects of bile duct ligation on hepatic expression of female‐specific CYP2C12 in male and female rats (1998) (31)
- Is bacterial ash the flash that ignites NASH? (2001) (31)
- Mouse models of non‐alcoholic steatohepatitis: A reflection on recent literature (2018) (30)
- Chronic ethanol consumption disrupts complexation between EGF receptor and phospholipase C-gamma1: relevance to impaired hepatocyte proliferation. (1999) (30)
- Non‐Alcoholic Fatty Liver and Non‐Alcoholic Steatohepatitis (2008) (30)
- Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. (1989) (30)
- Influence of clinicopathological variables on CYP protein expression in human liver (1996) (30)
- Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection (2002) (30)
- Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression (2003) (29)
- Impaired expression of microsomal cytochrome P450 2C11 in choline-deficient rat liver during the development of cirrhosis. (1992) (28)
- Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese mice. (2017) (28)
- Dietary modification dampens liver inflammation and fibrosis in obesity‐related fatty liver disease (2013) (27)
- Hepatitis C: an economic evaluation of extended treatment with interferon (1999) (27)
- Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study (2016) (27)
- Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha (2000) (26)
- Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease (1996) (26)
- Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon‐induced changes in chronic hepatitis B disease activity (1989) (26)
- Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. (1993) (25)
- Exercise retards hepatocarcinogenesis in obese mice independently of weight control. (2020) (24)
- Hepatitis B in Australia: determinants of intrafamily spread. (1987) (24)
- Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis (2018) (24)
- Non-alcoholic Fatty Liver Disease: Not Time for an Obituary Just Yet! (2020) (23)
- Portal vein ligation selectively lowers hepatic cytochrome P450 levels in rats (1983) (23)
- Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. (1996) (23)
- Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis (2018) (23)
- Overview: An Introduction to NASH and Related Fatty Liver Disorders (2007) (23)
- Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. (1984) (23)
- Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C (1993) (22)
- Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in ratsselectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats (1993) (22)
- Individualisation of antiviral therapy for chronic hepatitis C (2010) (22)
- Effects of portal vein ligation on sex hormone metabolism in male rats: relationship to lowered hepatic cytochrome P450 levels. (1986) (22)
- Acute atorvastatin is hepatoprotective against ischaemia‐reperfusion injury in mice by modulating eNOS and microparticle formation (2015) (22)
- Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. (2014) (21)
- Role of human hepatic cytochromes P450 in drug metabolism and toxicity. (1991) (21)
- Long‐Term Fate of Human Fetal Liver Progenitor Cells Transplanted in Injured Mouse Livers (2018) (20)
- Hepatocellular carcinoma in western Sydney (1994) (20)
- Selective reactivation of steroid hydroxylases following dissociation of the isosafrole metabolite complex with rat hepatic cytochrome P-450. (1986) (20)
- Hepatic heme metabolism and cytochrome P450 in cirrhotic rat liver. (1985) (20)
- The damage-associated molecular pattern HMGB1 is released early after clinical hepatic ischemia/reperfusion. (2019) (20)
- Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C (2005) (20)
- Will non‐invasive markers replace liver biopsy for diagnosing and staging fibrosis in non‐alcoholic steatohepatitis? (2009) (20)
- 220 Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial (2003) (19)
- Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis (2016) (19)
- Specific involvement of G(alphai2) with epidermal growth factor receptor signaling in rat hepatocytes, and the inhibitory effect of chronic ethanol. (2001) (19)
- Cytochrome P-450 heme moiety. The specific target in drug-induced heme alkylation. (1981) (19)
- Effectiveness of interferon alfa‐2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting (2003) (19)
- Effects of disease on expression and regulation of CYPs. (1999) (19)
- Histological features of non‐alcoholic fatty liver disease: What is important? (2012) (19)
- Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. (1993) (19)
- Interferon alfa for chronic active hepatitis B (1995) (19)
- Hepatocellular carcinoma after sustained response to interferon in non‐cirrhotic hepatitis C: Flaws in the cure, or a clue to the flaws? (1999) (19)
- Effect of genetic obesity and experimental diabetes on hepatic microsomal mixed function oxidase activities (1990) (18)
- Mechanism of halothane‐induced liver injury: Is it immune or metabolic idiosyncrasy? (1988) (18)
- Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. (2007) (17)
- Different effects of carbon tetrachloride toxicity and cirrhosis on substrate binding to rat hepatic microsomal cytochrome P-450. (1984) (17)
- 2,5-Di(tert-butyl)-1,4-benzohydroquinone--a novel mobilizer of the inositol 1,4,5-trisphosphate-sensitive Ca2+ pool. (1990) (17)
- Liver Disease caused by drugs (2010) (16)
- Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice (2011) (16)
- Non-Alcoholic Fatty Liver Disease: A Practical Guide (2013) (16)
- Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver (2019) (15)
- Practical Approach to the Diagnosis and Management of People With Fatty Liver Diseases (2007) (15)
- Interferon suppresses the isoform-specific activities of hepatic cytochrome P450 in female rats. (1992) (15)
- Ethanol perturbs receptor-operated cytosolic free calcium concentration signals in cultured rat hepatocytes. (1997) (15)
- Role of the oestrogen receptor in liver regeneration in the male rat (1993) (15)
- PNPLeAse get the fats right: Does lipogenesis or lipolysis cause NASH? 1 (2010) (15)
- Effects of extracellular Ca2+ and HCO3- on epidermal growth factor-induced DNA synthesis in cultured rat hepatocytes. (1995) (15)
- Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance (2002) (14)
- Investigation of focal hepatic lesions: Is tomographic red blood cell imaging useful? (1990) (14)
- Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. (2020) (14)
- Liver regeneration in obese mice with fatty livers: Does the impairment have relevance for other types of fatty liver disease? (2002) (13)
- NASH is an In fl ammatory Disorder : Pathogenic , Prognostic and Therapeutic Implications (2012) (13)
- Drugs and the liver updated, 2002. (2002) (13)
- NF-κB protects rat ARL-6 hepatocellular carcinoma cells against hydrogen peroxide-induced apoptosis (2005) (13)
- Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C (2014) (12)
- Carbamazepine hepatitis: the clinicopathological spectrum (1986) (12)
- Should we lower lipids in nonalcoholic fatty liver disease? (2014) (12)
- Hepatic testosterone metabolism in male rats with portal bypass. (1988) (11)
- Effects of hepatitis G virus coinfection on severity of hepatitis C: Relationship to risk factors and response to interferon treatment (1998) (11)
- Adverse Effects of Hormones and Hormone Antagonists on the Liver (2013) (11)
- Halothane‐induced liver injury in guinea‐pigs: Importance of cytochrome P450 enzyme activity and hepatic blood flow (1996) (11)
- Interferon treatment for chronic viral hepatitis in Australia: is it worth it? (1992) (11)
- Impaired bile flow and disordered hepatic calcium homeostasis are early features of halothane‐induced liver injury in guinea pigs (1996) (10)
- TNF‐α as therapeutic target in NASH: tried, but not yet proven (2007) (10)
- Mechanistic aspects of the inhibition of microsomal drug oxidation by primaquine. (1986) (10)
- Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence (2020) (10)
- Heme enhances hexobarbital metabolism in perfused rat liver after drug-mediated destruction of cytochrome P-450. (1981) (10)
- Exogenous heme restores in vivo functional capacity of hepatic cytochrome P-450 destroyed by allylisopropylacetamide. (1979) (10)
- Effects of metyrapone on expression of CYPs 2C11, 3A2, and other 3A genes in rat hepatocytes cultured on matrigel. (1996) (10)
- Pretranslational down-regulation of male specific hepatic P450s after portal bypass. (1994) (10)
- TNF-alpha as therapeutic target in NASH: tried, but not yet proven. (2007) (10)
- Cerebrospinal fluid gamma-aminobutyric acid levels in dogs with chronic portosystemic encephalopathy. (1986) (10)
- Human cytochrome P450 isoforms. Their genetic heterogeneity and induction by omeprazole. (1990) (9)
- The effects of partial hepatectomy on serum sex steroids in humans (1992) (9)
- Identifying who is at risk of drug‐induced liver injury: Is human leukocyte antigen specificity the key? (2011) (9)
- Does hepatitis C virus play a role in “non‐viral” chronic liver disease? (1990) (8)
- Portal vein ligation selectively lowers hepatic cytochrome P450 levels in rats. (1983) (8)
- The hepatic side-effects of drugs. (1986) (8)
- Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: Diagnostic and management implications (2018) (8)
- Crigler-Najjar Type 1 syndrome: absence of hepatic bilirubin UDP-glucuronyl transferase activity and therapeutic responses to light. (1982) (8)
- Role of ciliary dysfunction in a new model of obesity and non-alcoholic steatohepatitis: the foz/foz mice (2014) (8)
- Altered hepatic calcium homeostasis in guinea pigs with halothane-induced hepatotoxicity. (1988) (8)
- Efflux of Bilirubin into Plasma following Hepatic Degradation of Exogenous Heme 1 2 (1980) (8)
- Gastroenterology in the Asian‐Pacific region in the new millennium: The role of the Journal of Gastroenterology and Hepatology (2000) (8)
- Eicosanoids released following inhibition of the endoplasmic reticulum Ca2+ pump stimulate Ca2+ efflux in the perfused rat liver. (1993) (7)
- Reciprocal control of apoptosis and proliferation in cultured rat hepatoma arl-6 cells: Roles of nutrient supply, serum, and oxidative stress (2000) (7)
- Research workshop: Techniques for primary culture of liver cells (1998) (7)
- Brain gamma-aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma gamma-aminobutyric acid-like activity. (1987) (7)
- Effects of primaquine on hepatic microsomal haemoproteins and drug oxidation. (1986) (7)
- Agent Orange: Your new look JGH (the improvements go deeper than the cover) (2007) (7)
- Fanconi's familial hypoplastic anaemia with some unusual features. (1976) (6)
- Brain gaba receptor binding and plasma gaba-like activity in a model of chronic hepatic encephalopathy in rats (1986) (6)
- Incorporation of haemoglobin haem into the rat hepatic haemoproteins tryptophan pyrrolase and cytochrome P-450. (1986) (6)
- Hepatic endoplasmic reticulum stress in obesity: Deeper insights into processes, but are they relevant to nonalcoholic steatohepatitis? (2011) (5)
- Ischaemic preconditioning lowers hepatic GSH and activates p38 and NFkappaB to promote cell cycle entry via cyclin D1: mechanism of protection against ischemia reperfusion injury in Micea brief period of hepatic ischaemia and reperfusion (preconditioning) (2002) (5)
- Modern Concepts in Gastroenterology (1986) (5)
- Animal Models of Steatohepatitis (2007) (5)
- Halothane hepatitis: Damage to peripheral blood mononuclear cells produced by electrophilic drug metabolites is Ca2+‐dependent (1989) (5)
- 1192 VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668 (2013) (5)
- Effects of long-term choline deficiency on hepatic microsomal cytochrome P-450-mediated steroid and xenobiotic hydroxylases in the female rat. (1988) (5)
- Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. (2002) (5)
- Asian Pacific Association for Study of the Liver (APASL) (2003) (4)
- Hepatic Steatosis in Chronic Hepatitis C Infection (2002) (4)
- Lessons from Lumiracoxib: Are cyclooxygenase‐2 inhibitors less hepatotoxic than non‐selective non‐steroidal anti‐inflammatory drugs? (2012) (4)
- themes Nonalcoholic Steatosis and Steatohepatitis II. Cytochrome P -450 enzymes and oxidative stress (2001) (4)
- 3. Chronic viral hepatitis (1998) (4)
- Different effects of short‐ and long‐term dietary choline‐deficiency on hepatic microsomal phospholipids and drug oxidation (1987) (3)
- Increase in Plasma Gaba-Like Factor That Is Not Gaba Itself in Acute and Chronic Models of Hepatic-Encephalopathy in Rats (1986) (3)
- Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH (2015) (3)
- Towards the eradication of hepatitis B in Australia. (1988) (3)
- Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease (2013) (3)
- Déjà vu, mais pas en anglais! Precautionary notes on publishing the same article in two languages (2007) (3)
- Interferon alfa-2b for chronic active hepatitis C: Interim results of an australian trial (1990) (3)
- Effects of chronic ethanol on the stress-activated protein kinases, P38 and JNK, and expression of c-jun and cyclin D1 in rat hepatocytes (2001) (3)
- Clinical Potential of Emerging New Agents in Hepatitis B (2000) (3)
- Pharmacotherapy of hepatocellular carcinoma (2003) (3)
- Diabetes and Non‐Alcoholic Fatty Liver Disease (2016) (3)
- Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κB or Akt/mTORC1 (2016) (3)
- 384 Chronic hepatitic C virus infection and insulin resistance: how do they interact, and what is the effect on hepatic fibrosis? (2003) (3)
- Hepatic microsomal metabolism of androst-4-ene-3,17-dione: relative importance of ring hydroxylation and aromatization in control and induced rat liver. (1988) (3)
- Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin resistant 1 high-fat diet fed foz / foz mice 2 3 (2014) (2)
- A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer (2013) (2)
- Two years versus six months of interferon therapy for chronic hepatitis C (1996) (2)
- Is past exposure to hepatitis A protective against progressive fibrosis in non‐alcoholic fatty liver disease? (2007) (2)
- Acute viral hepatitis. (1998) (2)
- Deriving and testing of dysplastic murine hepatocytes: A new platform in liver cancer research (2017) (2)
- 2. Acute viral hepatitis (1998) (2)
- NAFLD: A worldwide problem (2016) (2)
- Liver abscess: What determines the prognosis? (1986) (2)
- Interferon down-reguiates the steroid 6B-hydroxylase, cytochrome P-450 PCN-E (1989) (1)
- Voluntary exercise improves metabolic and hepatic phenotypes in dietary but not metabolic obesity in male mice (2019) (1)
- When the liver gets stiff, the tough get moving (2019) (1)
- Chapter 24. Recent Advances (2007) (1)
- Microsomal protein synthesis and response to cytochrome p 450 inducing agents in cirrhotic rat liver (1982) (1)
- Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function (1991) (1)
- P0919 : Defective thermogenic adaptation to high calorie intake: A contender in NASH pathogenesis in foz/foz mice (2015) (1)
- Alpha-interferon 2b in the treatment of chronic hepatitis C: interim report of the first multicentre Australian trial (1993) (1)
- Effects on serum albumin of response and relapse to lamivudine in patients with chronic hepatitis B (2000) (1)
- The A, B, C, D and E of viral hepatitis: new agents for old diseases. (1990) (1)
- Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-kB or Akt/mTORC1 (2016) (1)
- Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κ B or Akt / mTORC 1 (2016) (1)
- Hepatitis C: a current perspective. (1995) (1)
- 913 PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND ITS IMPACT ON LIVER INJURY IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B (2008) (1)
- Cost effectiveness of interferon in chronic active hepatitis C (1994) (1)
- Diabetes augments obesity in accelerating liver tumour development: role of oxidative stress-induced JNK signalling and DNA damage response (2017) (1)
- 2,5-Di(TERT-BUTYL)-1,4-BENZOHYDROQUINONE - TRISPHOSPHATE-SENSITIVE Ca2+ POOL A NOVEL MOBILIZER OF THE INOSITOL 1,4,5- (1990) (1)
- Liver Diseases Caused by Drugs (2006) (1)
- Lifestyle intervention in early liver disease: metabolic changes at 3 months (2006) (1)
- What is Non‐Alcoholic Fatty Liver Disease (NAFLD), and Why is it Important? (2013) (1)
- In vitro hepatotoxicity of azathioprine at pharmacologic concentrations: roles of xanthine oxidase, oxidative stress and mitochondrial injury (2002) (1)
- New heterocyclic modifiers of oxidative drug metabolism--I. 6-Substituted-2-aminobenzothiazoles. (1986) (1)
- Announcement: Eliminating redundant publication: Déjà vu from the East (1998) (1)
- A thank you note from the Editor‐in‐Chief (2012) (1)
- Non‐alcoholic fatty liver disease (2019) (1)
- Primary sclerosing cholangitis: correlation of hepatobiliary scintigraphy with clinical and laboratory status. (2006) (1)
- Impairment of liver regeneration produced in rats by chronic ethanol administration is associated with abrogation of receptor-operated calcium signalling (1995) (1)
- 702 Amelioration of MCD-associated steatohepatitis by CYP2E1 inhibition: implications for the role of extra-mitochondrial source of pro-oxidants (2003) (0)
- 358 Effect of NF-κB inhibition on cell proliferation and cell death on human HCC HUH7 cells (2004) (0)
- Hypertension and Cardiac Hypertrophy in the Fat Aussie Mouse: A Model of Obesity with Type II Diabetes (2013) (0)
- Increased non-shivering thermogenesis had preventive but no therapeutic effects on non-alcoholic steatohepatitis (2017) (0)
- The Journal of Gastroenterology and Hepatology, 10 years on (1996) (0)
- Hepatitis and Immunization (1986) (0)
- Activation of PPAR alpha-dependent pathways causes rapid regression of fibrosing steatohepatitis in MCD diet-fed mice (2003) (0)
- Editorial and Advertising Office (1999) (0)
- Chapter Thirty-Seven – Drug-induced hepatic injury (prevention) (2006) (0)
- Role of inflammation and insulin resistance in a new model of NASH: the foz/foz mice (2012) (0)
- Should we Lower Lipids in Nafld? (2013) (0)
- Invited commentary (2004) (0)
- 768 Cholesterol Augments High Fat Diet in Accelerating Liver Carcinogenesis: Roles of NASH Oxidative Stress DNA Damage and Hepatocyte Proliferation (2014) (0)
- Obeticholic Acid Ameliorates Non-Alcoholic Fatty Liver Disease by Improving Metabolic Profile in Dietary Obesity, but Not in Obese, Diabetic FOZ/FOZ Mice (2016) (0)
- Predictors for steatosis and fibrosis in chronic hepatitis C (2001) (0)
- Title Constitutive activation of NF-κ B in human hepatocellularcarcinoma : Evidence of a cytoprotective role Author ( s ) (2006) (0)
- A functional macrophage NADPH oxidase is not required for the pathogenesis of steatohepatitis in mice induced by methionine-choline deficient (MCD) dietary feeding (2005) (0)
- The Journal of Gastroenterology and Hepatology: The first five years … and the next (1991) (0)
- Fifty years of Australian gastroenterology and hepatology: A golden era of contributions to the region (2009) (0)
- Azathioprine and the TNF hepatotoxicity paradox: is NF-kappaB the key? (2002) (0)
- INTERNATIONAL DIGESTIVE DISEASE FORUM (2014) (0)
- Journal of Gastroenterology and Hepatology celebrates the first Asia–Pacific Digestive Week, Sydney, September 2001 (2002) (0)
- ampk activation prevents and reverses drug-induced mitochondrial damage in hepatocytes by regulating mitochondrial quality control : 1909 (2015) (0)
- Drug-induced hepatic injury : Molecular biology, pathogenesis and clinics (1997) (0)
- Rat hepatoma cells are more refractory than hepatocytes to apoptosisinduced by oxidative stress: Role of NF-κB (2000) (0)
- Increased hepatic microsomal CYP 2E1 protein in a rat nutritional model of non-alcoholic steatohepatitis (1995) (0)
- Supp Fig S2 (2016) (0)
- Hepatitis C and Hepatocellular Carcinoma: Implications for Pathogenesis and Treatment (2012) (0)
- Brown Adipose Tissue Stimulation as a New Approach to Fight Obesity and Metabolic Syndrome (2016) (0)
- Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? (2003) (0)
- P276 TLR9 MEDIATES ADIPOSE AND LIVER INFLAMMATION IN METABOLICALLY OBESE MURINE MODELS OF NON-ALCOHOLIC STEATOHEPATITIS (2014) (0)
- Abstract 5751: Dietary cholesterol promotes steatohepatitis-related hepatocellular carcinoma by inducing aberrant gene expression in metabolism and mutations in calcium signaling (2018) (0)
- Colour Plate Section (2004) (0)
- FOOD AND THE GUT. Edited by J. O. Hunter and V. Alun Jones (1986) (0)
- 650 Interleukin-6 mediates preconditioning in hepatic ischemia reperfusion injury (2003) (0)
- P253 ENDOPLASMIC RETICULUM STRESS DOES NOT CONTRIBUTE TO NASH PATHOGENESIS IN OBESE, DIABETIC MICE WITH METABOLIC SYNDROME (2014) (0)
- Specific involvement of Gαi2 with epidermal growth factor receptor signaling in rat hepatocytes, and the inhibitory effect of chronic ethanol22Abbreviations: EGFR, epidermal growth factor receptor; PLC-γ1, phospholipase C-γ1; Gαi, inhibitory guanine nucleotide-binding regulatory protein; [Ca2+]i, in (2001) (0)
- EXOGENOUS HEME FUNCTIONALLY RECONSTITUTES HEPATIC CYTOCHROME P-450 IN VIVO (1980) (0)
- Drug-induced liver injury: What would a liver doctor do? (2011) (0)
- Chronic ethanol impairs activation of p38 after partial hepatectomy in rats: temporal association with expession of cyclin D1 and relevance to impaired liver regeneration (2002) (0)
- 240 Inhibition of cjun and FADD protects hepatocytes against azathioprine-induced necrosis (2003) (0)
- 620 BLOOD PRESSURE AND CARDIAC WEIGHT INCREASED IN FOZ/FOZ MICE COMPARED WITH CONTROLS (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Geoffrey C. Farrell?
Geoffrey C. Farrell is affiliated with the following schools:
